Articles ,

Medicure Gains 4.76% to 7-Year Closing High of $4.40: Must See Biotech Stock Screen

NIA’s latest brand-new stock suggestion Medicure (TSXV: MPH) gained by 4.76% today to a 7-year closing high of $4.40 per share:

Medicure MPH stock chart showing 7-year closing high of $4.40

NIA has just conducted a stock screen of all biotech companies listed in the U.S. or Canada including the U.S. OTC which includes a large percentage of foreign listed biotech stocks. There are 494 biotech stocks with a market cap of US$5 million or above listed on either the NYSE, NYSE American, NASDAQ, OTC Markets, TSX, TSX Venture, or CSE.

We filtered these 494 biotech stocks for companies that are: 1) generating revenue, 2) have positive net cash positions, 3) have seen no dilution in the trailing twelve months, 4) have seen no dilution in the trailing ten years.

These are the remaining 1% of biotech companies that meet the above criteria:

Biotech stock screening results showing five qualifying companies

Only 5 out of 494 biotech stocks met the criteria and Medicure (TSXV: MPH) is by far the lowest market cap of the five. Medicure (TSXV: MPH) has a 100% chance of becoming one of NIA’s largest percentage gainers of all-time we are 100% sure of it!

Watch what happens. We will be proven right.

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.

Tag